Hot Stock's Alert: Johnson & Johnson (NYSE:JNJ), L Brands, Inc. (NYSE:LB)
- Author: Zachary Reyes Feb 28, 2017,
Feb 28, 2017, 17:00
Vetr lowered Johnson & Johnson from a "buy" rating to a "hold" rating and set a $117.54 target price on the stock.in a research note on Monday, November 7th. The firm owned 11,337 shares of the company's stock after buying an additional 565 shares during the period. TX increased its stake in shares of Johnson & Johnson by 6.0% in the second quarter.
Other large investors also recently made changes to their positions in the company. Its share price has risen 8.86% in three months and is up 3.94% for the last five trades. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. The Market Capitalization of the company stands at 331.7 Billion. Korea Investment CORP boosted its stake in shares of Johnson & Johnson by 14.0% in the third quarter. Itau Unibanco Holding S.A. acquired a new position in Johnson & Johnson during the third quarter worth approximately $104,000.
The company's consensus rating on Reuter's scale improved from 2.39 to 2.41 during a month.
Johnson & Johnson's (JNJ) witnessed a loss of -0.27% in recent trading period with closing price of $ 122.40.
Now we look at the Moving Averages, the 200-day is 5.44, the 50-day is 6.45 and the 20-day is 6.31. The Average Volume of the company is 6.81 Million and P/E (price to earnings) ratio is 20.67, while Forward P/E ratio is 16.63. The stock has been recently noted -2.90% off of the 52-week high of 126.07 and +16.55% off of the 52-week low of 105.04.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 24th.
Lowe's Companies, Inc. has a consensus outperform rating from 31 Wall Street analysts, and the number of shares now sold short amount to at least 0.71% of shares outstanding. The firm had revenue of $18.10 billion for the quarter, compared to analyst estimates of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. During the same quarter in the previous year, the company posted $1.44 EPS. For the Current Quarter, 19 analysts are projecting the mean EPS to be $1.81/share.
Johnson & Johnson (NYSE:JNJ)'s growth estimate is 1.7 percent for the current quarter. Investors of record on Tuesday, February 28th will be issued a $0.80 dividend. The ex-dividend date was Friday, November 18th.
While looking at the Stock's Performance, Johnson & Johnson now shows a Weekly Performance of 3.94%, where Monthly Performance is 8.8%, Quarterly performance is 8.86%, 6 Months performance is 4.1% and yearly performance percentage is 17.78%. Johnson & Johnson (NYSE:JNJ) now has a P/E Ratio of 20.64. Exxonmobil Investment Management Inc.
"Courier Capital LLC Has $7,525,000 Stake in Johnson & Johnson (JNJ)" was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of USA & worldwide copyright and trademark legislation.
JNJ has been the topic of a number of recent analyst reports.
Some buy side analysts are also providing their Analysis on Johnson & Johnson, where 2 analysts have rated the stock as Strong buy, 7 analysts have given a Buy signal, 13 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. Analysts set a 12-month price target of $125.06 a share.
Many research firms have provided their ratings on Johnson & Johnson (NYSE:JNJ) where Wells Fargo provided Market Perform rating on the stock on 26-Jan-17. The stock presently has an average rating of "Hold" and a consensus target price of $121.81. They now have a $124.53 price objective on the stock. The stock was sold at an average price of $117.29, for a total transaction of $2,580,380.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.11% of the company's stock.
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and womens health fields, nutritional and over-the-counter pharmaceutical products.